BTAI רווח נקי למניה ב-12 החודשים האחרונים BioXcel Therapeutics, Inc.

BioXcel Therapeutics (BTAI) repurposes medications using AI, offering the drug IGALMI for the treatment of bipolar disorder and schizophrenia. The synergy of neurobiology and algorithms enables the efficient search for treatments for psychiatric disorders. The current annual net income per share illustrates the profitability trend, where the value -4.23 captures this metric. However, high marketing and distribution expenses are constraining the growth of the business's net margin.

The metric is calculated as the ratio of total net income to the total number of outstanding shares for the year. This metric measures the actual return per security by stripping the financial result of the impact of share issuance. For BioXcel Therapeutics (BTAI), this reflects the efficiency of R&D expenditures and the retention of key neurobiologists through stock options. By analyzing the change in earnings per share over the last 12 months, an investor can determine the asset's readiness to break out of its sideways range. An upward trend in the line confirms the business's resilience.